Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis

Am J Surg Pathol. 2002 May;26(5):662-9. doi: 10.1097/00000478-200205000-00013.

Abstract

Chromosomal aberrations involving chromosome segment 12q13-15 are a common finding in a variety of benign mesenchymal tumors. The target gene encodes for HMGIC, a member of the high mobility group protein family. These proteins act as architectural transcription factors. HMGIC plays a role as a common genetic denominator in benign mesenchymal tumorigenesis. We report a case of hyaline vascular Castleman's disease with intragenic HMGIC rearrangement, due to a clonal cytogenetic aberration involving the long arm of chromosome 12 [46,XX, add(1)(q21),der(6)t(6;12) (q23;q15),add(7)(p22), -9,inv(9)(p11q13),del(12)(q15),+mar] obtained after short-term primary cultures. A combined immunocytologic-cytogenetic approach enabled us to demonstrate the exclusive presence of HMGIC rearrangement in anti-CD21 reactive follicular dendric cells. This finding confirms that a clonal proliferation of follicular dendritic cells occurs in the hyaline vascular variant of Castleman's disease. It also provides a possible molecular pathway explaining stromal overgrowths and stromal neoplasms developing from this disorder.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Castleman Disease / complications
  • Castleman Disease / genetics*
  • Castleman Disease / pathology*
  • Chromosomes, Human, Pair 12
  • Dendritic Cells, Follicular / pathology*
  • Female
  • Gene Rearrangement
  • HMGA2 Protein / genetics*
  • Humans
  • Hyalin
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Lymph Nodes / pathology
  • Mesenchymoma / etiology
  • Mesenchymoma / genetics
  • Mesenchymoma / pathology

Substances

  • HMGA2 Protein